Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16384378 | 1.00 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1RECQL | |
| SCHEMBL16384384 | 1.00 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1RECQL | |
| SCHEMBL14118103 | 0.87 | NOD1 (0.50) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL25355694 | 0.86 | FOLH1 (0.44) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL14118034 | 0.86 | FOLH1 (0.51) | FOLH1NOD1ALBCASP2 | |
| SCHEMBL25355690 | 0.86 | FOLH1 (0.44) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL13124556 | 0.86 | MEN1 (0.59) | MEN1KMT2AFOLH1RECQLALB | |
| SCHEMBL25968884 | 0.86 | MEN1 (0.59) | MEN1KMT2AFOLH1RECQLALB | |
| SCHEMBL14217259 | 0.86 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL14685783 | 0.85 | GLP1R (0.54) | MEN1KMT2AFOLH1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058879-A1 | Growth Hormone Compound Formulation | NOVO NORDISK HEALTHCARE AG (CH) | 2016-03-03 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-7786221-B2 | Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules | NEKTAR THERAPEUTICS (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090054590-A1 | Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | MEN1 335/4885KMT2A 3466/4885FOLH1 469/4885 |
| US-20160058879-A1 | Growth Hormone Compound Formulation | GHRHR, GHSR, GHITM | MEN1 72/4885KMT2A 2916/4885FOLH1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.